Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497285 | 0.94 | NPC1 (0.69) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL496820 | 0.82 | RXFP1 (0.59) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL496814 | 0.82 | MAPT (0.76) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL2030596 | 0.80 | RXFP1 (0.53) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL2031649 | 0.79 | RXFP1 (0.55) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL2027048 | 0.79 | RXFP1 (0.51) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL5524673 | 0.78 | RXFP1 (1.00) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL31146696 | 0.78 | RXFP1 (1.00) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL497344 | 0.78 | RXFP1 (0.65) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 | |
| SCHEMBL2029084 | 0.78 | MAPT (0.56) | SMN1; SMN2NPC1TSHRRAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110136803-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7671050-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080280907-A1 | Triazolophthalazines | AALTANA PHARMA AG (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1874775-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072612-A2 | TRIAZOLOPHTHALAZINES AS PDE2- INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280907-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | SMN1; SMN2 2158/4885NPC1 3725/4885TSHR 1052/4885 |
| US-20110136803-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | SMN1; SMN2 2158/4885NPC1 3725/4885TSHR 1052/4885 |
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | SMN1; SMN2 2158/4885NPC1 3725/4885TSHR 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.